HRP20190897T1 - Laki lanac humaniziranih miševa - Google Patents
Laki lanac humaniziranih miševa Download PDFInfo
- Publication number
- HRP20190897T1 HRP20190897T1 HRP20190897TT HRP20190897T HRP20190897T1 HR P20190897 T1 HRP20190897 T1 HR P20190897T1 HR P20190897T T HRP20190897T T HR P20190897TT HR P20190897 T HRP20190897 T HR P20190897T HR P20190897 T1 HRP20190897 T1 HR P20190897T1
- Authority
- HR
- Croatia
- Prior art keywords
- human
- mouse
- light chain
- gene
- nucleic acid
- Prior art date
Links
- 241000699670 Mus sp. Species 0.000 title claims 4
- 241000699666 Mus <mouse, genus> Species 0.000 claims 31
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 108091029795 Intergenic region Proteins 0.000 claims 4
- 241001529936 Murinae Species 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 231100000502 fertility decrease Toxicity 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 claims 2
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims 1
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims 1
- 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 102000053391 human F Human genes 0.000 claims 1
- 108700031895 human F Proteins 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108700031127 mouse Adam6a Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Claims (12)
1. Miš koji sadrži:
(a) jedan ili više nepreuređenih humanih genskih segmenata Vλ i jedan ili više nepreuređenih humanih genskih segmenata Jλ na lokusu endogenog imunoglobulinskog lakog lanca kapa miša, naznačen time, što imunoglobulinski lokus lakog lanca kapa sadrži mišju Cκ regiju;
(b) jedan ili više humanih genskih segmenata VH, jedan ili više humanih genskih segmenata DH i jedan ili više humanih genskih segmenata JH na lokusu endogenog imunoglobulinskog teškog lanca miša; i
(c) modifikaciju lokusa imunoglobulinskog teškog lanca, naznačenu time, što modifikacija eliminira endogenu ADAM6 funkciju, koja je povezana sa smanjenjem plodnosti kod mužjaka miševa, pri čemu miš dodatno sadrži sekvencu nukleinske kiseline koja šifrira mišji ADAM6a protein ili njegov ortolog ili homolog ili funkcionalni fragment, pri čemu je svaki funkcionalan radi poboljšanja ili obnavljanja spomenutog smanjenja plodnosti kod mužjaka miševa, i sekvencu nukleinske kiseline koja šifrira mišji ADAM6b protein ili njegov ortolog ili homolog ili funkcionalni fragment, pri čemu je svaki funkcionalan radi poboljšanja ili obnavljanja spomenutog smanjenja plodnosti kod mužjaka miševa, naznačeno time, što su sekvence nukleinske kiseline koje šifriraju ADAM6 proteine, njegove ortologe, homologe ili funkcionalne fragmente prisutne unutar genskih segmenata humanog teškog lanca.
2. Miš prema prethodnom patentnom zahtjevu, naznačen time, što miš sadrži od 12 do 40 humanih genskih segmenata Vλ i najmanje jedan humani genski segment Jλ.
3. Miš prema patentnom zahtjevu 2, naznačen time, što:
(a) miš sadrži 12 humanih genskih segmenata Vλ i najmanje jedan humani genski segment Jλ;
(b) miš sadrži 28 humanih genskih segmenata Vλ i najmanje jedan humani genski segment Vλ; ili
(c) miš sadrži 40 humanih genskih segmenata Vλ i najmanje jedan humani genski segment Jλ.
4. Miš prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što:
(a) najmanje jedan humani genski segment Jλ je odabran iz Jλ1, Jλ2, Jλ3, Jλ7 i njihove kombinacije; i/ili
(b) miš sadrži najmanje četiri humana genska segmenta Jλ.
5. Miš prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što miš ne posjeduje varijabilnu regiju endogenog lakog lanca kapa na lokusu endogenog imunoglobulinskog lakog lanca kapa.
6. Miš prema bilo kojem od prethodnih patentnih zahtjeva, koji dodatno sadrži humanu međugensku regiju Vκ-Jκ iz lokusa humanog lakog lanca κ, naznačen time, što se humana međugenska regija Vκ-Jκ graniči s jednim ili više nepreuređenih genskih segmenata Vλ i s jednim ili više nepreuređenih genskih segmenata Jλ, poželjno pri čemu se humana međugenska regija Vκ-Jκ nalazi između genskog segmenta Vλ i genskog segmenta Jλ, i naznačena time, što humana međugenska regija Vκ-Jκ sadrži SEQ ID NO. 158.
7. Miš prema bilo kojem od prethodnih patentnih zahtjeva, koji je mužjak miša.
8. Izolirana stanica ili tkivo iz miša prema bilo kojem od prethodnih patentnih zahtjeva.
9. Primjena miša prema bilo kojem patentnom zahtjevu od 1 do 7, za dobivanje:
(i) reverznog kimernog antitijela;
(ii) potpunog humanog antitijela;
(iii) potpuno humanog Fab fragmenta; ili
(iv) potpuno humanog F(ab)2 fragmenta.
10. Metoda za dobivanje antitijela, pri čemu se metoda sastoji od:
(a) izlaganja miša prema bilo kojem patentnom zahtjevu od 1 do 7 antigenu;
(b) dozvoljavanja mišu da razvije imunološki odgovor na antigen; i
(c) izoliranja iz miša iz (b) antitijela koje specifično prepoznaje antigen, naznačeno time, što antitijelo sadrži laki lanac dobiven iz hVλ, hJλ i mišje Cκ regije, ili izoliranja iz miša iz (b) stanice koja sadrži imunoglobulinsku domenu koja specifično prepoznaje antigen, ili identifikacije u mišu iz (b) sekvence nukleinske kiseline koja šifrira varijabilnu domenu teškog i/ili lakog lanca koja vezuje antigen.
11. Metoda za dobivanje humanog antitijela, pri čemu se metoda sastoji od izlaganja miša prema bilo kojem patentnom zahtjevu od 1 do 7 antigenu, dozvoljavanja mišu da ispolji imunološki odgovor koji se sastoji od stvaranja antitijela koje se specifično vezuje za antigen, identificiranja u B stanici iz miša preuređene sekvence nukleinske kiseline koja šifrira varijabilnu domenu humanog teškog lanca i preuređenu sekvencu nukleinske kiseline i preuređene sekvence nukleinske kiseline koja šifrira srodnu sekvencu varijabilne domene humanog lakog lanca, naznačena time, što se antitijelo specifično vezuje za antigen, i korištenja sekvenci nukleinske kiseline koje šifriraju varijabilnu domenu humanog teškog lanca odnosno varijabilnu domenu humanog lakog lanca za sekvencu nukleinske kiseline koja šifrira konstantnu domenu humanog teškog lanca odnosno sekvencu nukleinske kiseline koja šifrira konstantnu domenu humanog lakog lanca, kako bi se dobilo željeno antitijelo.
12. Metoda za dobivanje sekvence nukleinske kiseline koja šifrira varijabilnu domenu teškog i/ili lakog lanca koja se sastoji od:
(a) izlaganja miša prema bilo kojem patentnom zahtjevu od 1 do 7 antigenu;
(b) identifikacije u B stanici iz miša:
(i) gena imunoglobulina preuređenog lakog lanca, naznačeno time, što gen imunoglobulina preuređenog lakog lanca sadrži najmanje jedan genski segment varijabilne regije humanog lakog lanca λ povezan za mišju Cκ regiju; ili
(ii) gena imunoglobulina preuređenog lakog lanca iz (b)(i) i gena imunoglobulina preuređenog teškog lanca, naznačeno time, što gen imunoglobulina preuređenog teškog lanca šifrira teški lanac koji se uparuje s lakim lancem šifriranim genom imunoglobulina preuređenog lakog lanca iz (b)(i); i
(c) kloniranja sekvence nukleinske kiseline koja šifrira varijabilnu domenu teškog i/ili lakog lanca iz B stanice miša, naznačeno time, što je varijabilna domena teškog i/ili lakog lanca iz antitijela koje sadrži humani Vλ i mišji Cκ.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578097P | 2011-12-20 | 2011-12-20 | |
| EP12809955.3A EP2793567B1 (en) | 2011-12-20 | 2012-12-17 | Humanized light chain mice |
| PCT/US2012/069981 WO2013096142A1 (en) | 2011-12-20 | 2012-12-17 | Humanized light chain mice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190897T1 true HRP20190897T1 (hr) | 2019-09-20 |
Family
ID=47501484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190897TT HRP20190897T1 (hr) | 2011-12-20 | 2019-05-15 | Laki lanac humaniziranih miševa |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9706759B2 (hr) |
| EP (2) | EP3527070A1 (hr) |
| JP (5) | JP6327750B2 (hr) |
| KR (5) | KR101924805B1 (hr) |
| CN (1) | CN104159444B (hr) |
| AU (5) | AU2012323987B2 (hr) |
| BR (2) | BR122021007339B1 (hr) |
| CA (1) | CA2859408C (hr) |
| CY (1) | CY1121638T1 (hr) |
| DK (1) | DK2793567T3 (hr) |
| ES (1) | ES2720186T3 (hr) |
| HK (1) | HK1202772A1 (hr) |
| HR (1) | HRP20190897T1 (hr) |
| HU (1) | HUE044266T2 (hr) |
| IL (3) | IL233153B (hr) |
| IN (1) | IN2014DN06094A (hr) |
| LT (1) | LT2793567T (hr) |
| ME (1) | ME03477B (hr) |
| MX (2) | MX356429B (hr) |
| MY (1) | MY173936A (hr) |
| PL (1) | PL2793567T3 (hr) |
| PT (1) | PT2793567T (hr) |
| RS (1) | RS58761B1 (hr) |
| RU (2) | RU2664181C2 (hr) |
| SG (3) | SG10201913164YA (hr) |
| SI (1) | SI2793567T1 (hr) |
| TR (1) | TR201903439T4 (hr) |
| WO (1) | WO2013096142A1 (hr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| ES2758974T5 (es) | 2011-02-25 | 2023-06-08 | Regeneron Pharma | Ratones ADAM6 |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| ES2906462T3 (es) * | 2011-10-17 | 2022-04-18 | Regeneron Pharma | Ratones de cadena pesada de inmunoglobulina restringida |
| US20180295821A1 (en) * | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| KR101924805B1 (ko) | 2011-12-20 | 2018-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| DK3597038T3 (da) * | 2012-02-01 | 2021-06-28 | Regeneron Pharma | Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| KR102381716B1 (ko) | 2012-06-12 | 2022-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
| WO2014130690A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
| SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
| SG11201607015VA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2017035252A1 (en) * | 2015-08-24 | 2017-03-02 | Trianni, Inc. | Enhanced production of immunoglobulins |
| WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| EP3457840B1 (en) | 2016-05-20 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
| WO2017214089A1 (en) * | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| EP4082334A1 (en) * | 2016-11-04 | 2022-11-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| SG11201906540WA (en) * | 2017-01-19 | 2019-08-27 | Open Monoclonal Tech Inc | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
| NZ760232A (en) | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| SG11202003044SA (en) * | 2017-12-05 | 2020-04-29 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
| TW202003564A (zh) * | 2018-03-24 | 2020-01-16 | 美商再生元醫藥公司 | 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途 |
| CA3100021A1 (en) | 2018-05-17 | 2019-11-21 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| CN109359045B (zh) * | 2018-10-16 | 2022-01-04 | 武汉斗鱼网络科技有限公司 | 一种测试方法、装置、设备和存储介质 |
| JP2020146317A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146307A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146297A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146303A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146313A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146309A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146310A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146314A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146306A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146300A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146316A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146311A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146318A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146299A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146298A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146305A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146301A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146302A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146315A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146308A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| JP2020146304A (ja) * | 2019-03-14 | 2020-09-17 | 株式会社三洋物産 | 遊技機 |
| KR20220016880A (ko) * | 2019-06-05 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도 |
| WO2021003152A1 (en) * | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| DK3785536T3 (da) * | 2019-08-28 | 2022-03-28 | Trianni Inc | Adam6-knockin-mus |
| AU2021342159A1 (en) * | 2020-09-11 | 2023-03-02 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| JP7448858B2 (ja) | 2020-10-02 | 2024-03-13 | 日亜化学工業株式会社 | 光源装置及び導光アレイ部 |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| BR112023021256A2 (pt) | 2021-04-20 | 2023-12-12 | Regeneron Pharma | Anticorpos humanos para artemina e métodos de uso dos mesmos |
| WO2024015816A1 (en) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993012227A1 (en) * | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US7041871B1 (en) * | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| WO1994012215A1 (en) | 1992-12-01 | 1994-06-09 | Protein Design Labs, Inc. | Humanized antibodies reactive with l-selectin |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US6632976B1 (en) | 1995-08-29 | 2003-10-14 | Kirin Beer Kabushiki Kaisha | Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene |
| CA2250830A1 (en) | 1996-06-26 | 1997-12-31 | Binhai Zheng | Chromosomal rearrangement by insertion of two recombination substrates |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| WO1999050657A1 (en) * | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| RU10506U1 (ru) | 1999-04-08 | 1999-08-16 | Кривулин Виталий Николаевич | Ручной культиватор |
| WO2000073323A2 (en) | 1999-05-27 | 2000-12-07 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
| GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| GB0031284D0 (en) | 2000-12-21 | 2001-01-31 | Ks Biomedix Ltd | High affinity antibodies |
| US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
| CA2508763C (en) | 2001-05-11 | 2012-01-24 | Kirin Beer Kabushiki Kaisha | Human antibody producing mouse and method for producing human antibody using the same |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| WO2003031656A1 (en) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Genetic testing for male factor infertility |
| US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
| JP2005510253A (ja) | 2001-11-30 | 2005-04-21 | アブジェニックス インコーポレイテッド | ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物 |
| US20030217171A1 (en) | 2002-05-17 | 2003-11-20 | Von Stuermer Wolfgang R. | Self-replicating and self-installing software apparatus |
| JP4099646B2 (ja) | 2002-06-04 | 2008-06-11 | 株式会社安川電機 | ボイスコイルモータ |
| PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
| ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| GB0230201D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| AU2004257292A1 (en) | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| CN1605628A (zh) | 2003-09-03 | 2005-04-13 | 中国疾病预防控制中心病毒病预防控制所 | Cho细胞生产的人源抗甲肝病毒基因工程抗体 |
| RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
| CA2827654C (en) | 2004-10-19 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| ES2318384T3 (es) | 2005-06-30 | 2009-05-01 | Borealis Technology Oy | Capa exterior de funda para cables de potencia o de comuniccion. |
| GB0618345D0 (en) | 2006-09-18 | 2006-10-25 | Univ Erasmus | Binding molecules |
| JP5184374B2 (ja) | 2006-01-25 | 2013-04-17 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 対立遺伝子排除 |
| GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
| CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| CN101501073A (zh) | 2006-08-22 | 2009-08-05 | G2英弗勒美欣私人有限公司 | 抗体制备方法 |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
| EP2669298A3 (en) | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| NZ592308A (en) | 2008-09-30 | 2012-11-30 | Ablexis Llc | Non-human mammals for the production of chimeric antibodies |
| CN112680475A (zh) | 2008-12-18 | 2021-04-20 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
| US20120204278A1 (en) * | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| PT2954779T (pt) | 2009-12-10 | 2019-05-29 | Regeneron Pharma | Ratinhos que produzem anticorpos de cadeia pesada |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| EP3095871B1 (en) | 2010-02-08 | 2019-04-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| CN105695415A (zh) | 2010-06-17 | 2016-06-22 | 科马布有限公司 | 动物模型及治疗分子 |
| DK2905338T3 (da) | 2010-06-22 | 2017-11-06 | Regeneron Pharma | Transgene mus med et modificeret endogent lambda immunglobulin-locus |
| NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| WO2012063048A1 (en) | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| ES2758974T5 (es) | 2011-02-25 | 2023-06-08 | Regeneron Pharma | Ratones ADAM6 |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| ES2906462T3 (es) | 2011-10-17 | 2022-04-18 | Regeneron Pharma | Ratones de cadena pesada de inmunoglobulina restringida |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| KR101924805B1 (ko) | 2011-12-20 | 2018-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| DK3597038T3 (da) | 2012-02-01 | 2021-06-28 | Regeneron Pharma | Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
-
2012
- 2012-12-17 KR KR1020147020454A patent/KR101924805B1/ko active IP Right Grant
- 2012-12-17 LT LTEP12809955.3T patent/LT2793567T/lt unknown
- 2012-12-17 SG SG10201913164YA patent/SG10201913164YA/en unknown
- 2012-12-17 RS RS20190641A patent/RS58761B1/sr unknown
- 2012-12-17 MY MYPI2014001743A patent/MY173936A/en unknown
- 2012-12-17 SI SI201231572T patent/SI2793567T1/sl unknown
- 2012-12-17 RU RU2014127339A patent/RU2664181C2/ru active
- 2012-12-17 DK DK12809955.3T patent/DK2793567T3/en active
- 2012-12-17 MX MX2014007682A patent/MX356429B/es active IP Right Grant
- 2012-12-17 SG SG10201605675WA patent/SG10201605675WA/en unknown
- 2012-12-17 ES ES12809955T patent/ES2720186T3/es active Active
- 2012-12-17 EP EP19151471.0A patent/EP3527070A1/en active Pending
- 2012-12-17 PL PL12809955T patent/PL2793567T3/pl unknown
- 2012-12-17 RU RU2018119366A patent/RU2761639C2/ru active
- 2012-12-17 CA CA2859408A patent/CA2859408C/en active Active
- 2012-12-17 IN IN6094DEN2014 patent/IN2014DN06094A/en unknown
- 2012-12-17 KR KR1020197031617A patent/KR102081657B1/ko active IP Right Grant
- 2012-12-17 WO PCT/US2012/069981 patent/WO2013096142A1/en active Application Filing
- 2012-12-17 AU AU2012323987A patent/AU2012323987B2/en active Active
- 2012-12-17 ME MEP-2019-143A patent/ME03477B/me unknown
- 2012-12-17 KR KR1020187034431A patent/KR102038974B1/ko active IP Right Grant
- 2012-12-17 JP JP2014549157A patent/JP6327750B2/ja active Active
- 2012-12-17 HU HUE12809955 patent/HUE044266T2/hu unknown
- 2012-12-17 EP EP12809955.3A patent/EP2793567B1/en active Active
- 2012-12-17 TR TR2019/03439T patent/TR201903439T4/tr unknown
- 2012-12-17 CN CN201280070209.4A patent/CN104159444B/zh active Active
- 2012-12-17 BR BR122021007339-2A patent/BR122021007339B1/pt active IP Right Grant
- 2012-12-17 PT PT12809955T patent/PT2793567T/pt unknown
- 2012-12-17 KR KR1020207026010A patent/KR102186822B1/ko active IP Right Grant
- 2012-12-17 KR KR1020207004911A patent/KR102156139B1/ko active IP Right Grant
- 2012-12-17 SG SG11201403326VA patent/SG11201403326VA/en unknown
- 2012-12-17 US US13/716,238 patent/US9706759B2/en active Active
- 2012-12-17 BR BR112014015238-1A patent/BR112014015238B1/pt active IP Right Grant
-
2013
- 2013-07-26 US US13/951,996 patent/US9622459B2/en active Active
-
2014
- 2014-06-16 IL IL233153A patent/IL233153B/en active IP Right Grant
- 2014-06-20 MX MX2021000298A patent/MX2021000298A/es unknown
-
2015
- 2015-04-10 HK HK15103528.8A patent/HK1202772A1/xx unknown
- 2015-10-07 AU AU2015238803A patent/AU2015238803B2/en active Active
-
2016
- 2016-12-13 JP JP2016240915A patent/JP2017046722A/ja not_active Withdrawn
-
2017
- 2017-05-02 US US15/585,023 patent/US10561124B2/en active Active
- 2017-10-26 AU AU2017251797A patent/AU2017251797B2/en active Active
-
2018
- 2018-04-09 IL IL258561A patent/IL258561B/en active IP Right Grant
- 2018-11-16 JP JP2018215387A patent/JP6728308B2/ja active Active
-
2019
- 2019-04-28 IL IL266268A patent/IL266268B/en active IP Right Grant
- 2019-05-15 HR HRP20190897TT patent/HRP20190897T1/hr unknown
- 2019-05-17 CY CY20191100525T patent/CY1121638T1/el unknown
- 2019-12-30 US US16/729,798 patent/US11617357B2/en active Active
- 2019-12-30 US US16/729,852 patent/US11612151B2/en active Active
-
2020
- 2020-03-04 AU AU2020201596A patent/AU2020201596B2/en active Active
- 2020-07-01 JP JP2020113809A patent/JP7152447B2/ja active Active
-
2022
- 2022-08-24 AU AU2022221449A patent/AU2022221449A1/en active Pending
- 2022-09-29 JP JP2022156704A patent/JP2022180594A/ja active Pending
-
2023
- 2023-02-15 US US18/110,276 patent/US20230337646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190897T1 (hr) | Laki lanac humaniziranih miševa | |
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| HRP20171357T1 (hr) | Ograničeni teški lanac imunoglobulina u miševa | |
| HRP20210916T1 (hr) | Miševi s ljudskim univerzalnim lakim lancem | |
| HRP20161551T4 (hr) | Miš sa zajedničkim lakim lancem | |
| HRP20191333T1 (hr) | Glodavci koji izražavaju sekvence imunoglobulina osjetljive na ph vrijednost | |
| HRP20170322T1 (hr) | Miševi koji stvaraju vl vezne proteine | |
| HRP20190706T1 (hr) | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina | |
| JP2017114866A5 (hr) | ||
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| ES2655877T3 (es) | Composiciones y métodos para aumentar el crecimiento muscular | |
| HRP20201153T1 (hr) | Pd-1 sredstva visokog afiniteta i načini uporabe | |
| DK2738259T1 (da) | ADAM6 mus | |
| HRP20160497T1 (hr) | Mišji hibridni laki lanac | |
| HRP20180226T1 (hr) | Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc | |
| JP2015519055A5 (hr) | ||
| JP2016512034A5 (hr) | ||
| KR20180077144A (ko) | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 | |
| JP2014524243A5 (hr) | ||
| JP2015505477A5 (hr) | ||
| HRP20220787T1 (hr) | Protutijela protiv garp-tgf-beta | |
| JP2017531443A (ja) | Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法 | |
| JP2013507970A5 (hr) | ||
| HRP20150639T1 (hr) | Postupak za proäśišä†avanje proteina | |
| Lu et al. | Frontier of therapeutic antibody discovery: The challenges and how to face them |